Granted Patent
B2
US 12,324,855 · App. 18/316,829 · Granted Jun 10, 2025
Method of safe administration of phosphorylated Tau peptide vaccine
Inventors:
Andrea Pfeifer (St. Legier, CH); Andreas Muhs (Cugy, CH); Maria Pihlgren Bosch (Mont-sur-Lausanne, CH); Marija Vukicevic Verhille (St-Sulpice, CH); Nicolas Piot (Grandvaux, CH); Saroj Raj Ghimire (Chavannes-Pres-Renens, CH); Elizabeth Anne Ramsburg (Chalfont, PA); Donata De Marco (Turnhout, BE); Charlotte Sadaka (San Diego, CA)
A61K9/1271A61K39/0007A61P25/28A61K2039/545A61K2039/55516A61K2039/55555A61K2039/55561A61K2039/55572A61K2039/6018A61K2039/627
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods for inducing anti-phosphorylated Tau antibodies without inducing a severe adverse event in humans are described. The methods include administering to the subject an effective amount of liposomes including a toll-like receptor 4 agonist and a Tau phosphopeptide presented on the surface of the liposome.
Claims (26)
1. A method of inducing anti-phosphorylated Tau antibodies without inducing a severe adverse event in a human subject in need thereof, comprising administering to the subject an effective amount of liposomes comprising a toll-like receptor 4 agonist and a Tau phosphopeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 5, 9 and 12, wherein the Tau phosphopeptide is administered at an amount of about 25 nmoles to about 750 nmoles per dose, and the Tau phosphopeptide is presented on the surface of the liposome.
2. The method of claim 1 , wherein the Tau phosphopeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 28, 31, 35 and 38.
3. The method of claim 1 , wherein the effective amount of liposomes comprises 300 μg to 2400 μg per dose of the Tau phosphopeptide.
4. The method of claim 3 , wherein the effective amount of liposomes comprises 300 μg per dose, 900 μg per dose, 1800 μg per dose, or 2400 μg per dose of the Tau phosphopeptide.
5. The method of claim 1 , wherein the liposomes are administered subcutaneously.
6. The method of claim 1 , wherein the liposomes are administered intramuscularly.
7. The method of claim 1 , wherein the liposome further comprises a helper T-cell epitope and a lipidated CpG oligonucleotide.
8. The method of claim 7 , wherein the lipidated CpG oligonucleotide has a nucleotide sequence selected from the group consisting of SEQ ID NO:18 to SEQ ID NO:22, wherein the CpG oligonucleotide has one or more phosphorothioate internucleotide linkages, and the CpG oligonucleotide is covalently linked to at least one lipophilic group, optionally via a PEG linker.
9. The method of claim 8 , wherein the CpG oligonucleotide is covalently linked to at least one lipophilic group via a PEG linker.
10. The method of claim 1 , wherein the liposome further comprises one or more lipids selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-sn-glycero-3-phosphoryl-3′-rac-glycerol (DMPG), and cholesterol.
11. The method of claim 7 , wherein the helper T-cell epitope comprises at least one amino acid sequence selected from the group consisting of SEQ ID NO: 13 to SEQ ID NO: 17, SEQ ID NO:23 to SEQ ID NO:26, and SEQ ID NO:39 to SEQ ID NO:44.
12. The method of claim 7 , wherein the effective amount of liposomes comprises the helper T-cell epitope at an amount of about 2 nmoles to about 110 nmoles per dose.
13. The method of claim 7 , wherein the effective amount of liposomes comprises the helper T-cell epitope having an amino acid sequence selected from the group consisting of SEQ ID NO: 13 to SEQ ID NO:17, SEQ ID NO:23 to SEQ ID NO:26, and SEQ ID NO: 39 to SEQ ID NO:44 at an amount of 25 μg to 620 μg per dose.
14. The method of claim 1 , wherein the effective amount of liposomes comprises the toll-like receptor 4 agonist at an amount of 30 μg to 900 μg per dose.
15. The method of claim 7 , wherein the effective amount of liposomes comprises the lipidated CpG oligonucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NO: 18 to SEQ ID NO:22 at an amount of 50 μg to 1250 μg per dose.
16. The method of claim 1 , wherein the liposome comprises:
(1) the Tau phosphopeptide having the amino acid sequence of SEQ ID NO:28;
(2) the toll-like receptor 4 agonist comprising monophosphoryl hexa-acyl Lipid A, 3-deacyl;
(3) the helper T-cell epitope comprising the amino acid sequence of SEQ ID NO: 39;
(4) the lipidated CpG oligonucleotide comprising the nucleotide sequence of SEQ ID NO: 18; and
(5) at least one lipid selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-sn-glycero-3-phosphoryl-3′-rac-glycerol (DMPG), and cholesterol,
wherein the effective amount of liposomes comprises the helper T-cell epitope at an amount of about 75 nmoles to about 450 nmoles per dose.
17. The method of claim 1 , wherein the subject is in need of a treatment of Alzheimer's Disease.
18. The method of claim 17 , wherein the subject is in need of a treatment of early Alzheimer's Disease, mild cognitive impairment (MCI) due to Alzheimer's Disease, or mild to moderate Alzheimer's Disease.
19. The method of claim 14 , wherein the effective amount of liposomes comprises the toll-like receptor 4 agonist at an amount of 100 μg to 585 μg per dose.
20. The method of claim 15 , wherein the effective amount of liposomes comprises the lipidated CpG oligonucleotide at an amount of 150 μg to 800 μg per dose.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 12, 2023
From: PFEIFER, ANDREA; PIHLGREN BOSCH, MARIA; VUKICEVIC VERHILLE, MARIJA; PIOT, NICOLAS; GHIMIRE, SAROJ RAJ
To: AC IMMUNE SA
Reel/Frame 063629/0464 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 12, 2023
From: MUHS, ANDREAS
To: AC IMMUNE SA
Reel/Frame 063629/0498 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 12, 2023
From: RAMSBURG, ELIZABETH ANNE; DE MARCO, DONATA; SADAKA, CHARLOTTE
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 063629/0534 →
Continuity (3)
Provisional Application
62802870
· Feb 8, 2019
References Cited (166)
US 5843779A
· Vandermeeren
· 1998
[cited by applicant]
US 6444793B1
· Pepinsky
· 2002
[cited by applicant]
US 7408027B1
· Mandelkow
· 2008
[cited by applicant]
US 7741297B2
· Jiang
· 2010
[cited by applicant]
US 8647631B2
· Pfeifer
· 2014
[cited by applicant]
US 8748386B2
· Sigurdsson
· 2014
[cited by applicant]
US 9353127B2
· Fishkin et al.
· 2016
[cited by applicant]
US 9687447B2
· Reis
· 2017
[cited by applicant]
US 20010025320A1
· Seng
· 2001
[cited by applicant]
US 20020086009A1
· Ishiguro
· 2002
[cited by applicant]
US 20030232758A1
· St George-Hyslop
· 2003
[cited by applicant]
US 20050038239A1
· Catchpole
· 2005
[cited by applicant]
US 20050221391A1
· Davies
· 2005
[cited by applicant]
US 20050261475A1
· Tseng
· 2005
[cited by applicant]
US 20080220449A1
· Vasan
· 2008
[cited by applicant]
US 20130022982A1
· Wang
· 2013
[cited by applicant]
US 20140314837A1
· Pfeifer
· 2014
[cited by applicant]
US 20160008443A1
· Mandler
· 2016
[cited by applicant]
US 20210388044A1
· Ramsburg
· 2021
[cited by applicant]
CN 105121465
· 2015
[cited by applicant]
EA 003739
· 2003
[cited by applicant]
EP 2210901A1
· 2010
[cited by applicant]
EP 2269633
· 2011
[cited by applicant]
JP 5819401
· 2015
[cited by applicant]
TW 461209
· 2001
[cited by applicant]
WO 9014837A1
· 1990
[cited by applicant]
WO 1996020218A1
· 1996
[cited by applicant]
WO 1997034145A1
· 1997
[cited by applicant]
WO 1998022120A1
· 1998
[cited by applicant]
WO 2003066649A1
· 2003
[cited by applicant]
WO 2004058258
· 2004
[cited by applicant]
WO 2005080986A1
· 2005
[cited by applicant]
WO 2005081872A2
· 2005
[cited by applicant]
WO 2007068105A1
· 2007
[cited by applicant]
WO 2007068411A2
· 2007
[cited by applicant]
WO 2007098607
· 2007
[cited by applicant]
WO 2010088411
· 2010
[cited by applicant]
WO 2010106127A2
· 2010
[cited by applicant]
WO 2010115843A2
· 2010
[cited by applicant]
WO 2010144711A2
· 2010
[cited by applicant]
WO 2011013034A1
· 2011
[cited by applicant]
WO 2012020124A1
· 2012
[cited by applicant]
WO 2012055933A1
· 2012
[cited by applicant]
WO 2013041962
· 2013
[cited by applicant]
WO 2014031694
· 2014
[cited by applicant]
WO 2015197823A2
· 2015
[cited by applicant]
WO 2017011590
· 2017
[cited by applicant]
WO 2018106781A1
· 2018
[cited by applicant]
WO 2019084118A2
· 2019
[cited by applicant]
WO 2019094595A2
· 2019
[cited by applicant]
WO 2020219646
· 2020
[cited by applicant]
Peeraer et al., “Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice”, Neurobiol. Dis. Jan. 2015, 73, 83-95.
[cited by applicant]
Ribe et aL, “Accelerated Amyloid Deposition, Neurofibrillary Degeneration and Neuronal Loss in Double Mutant APP/TAU Transgenic Mice,” Neurobiology of Disease, vol. 20, pp. 814-822 (2005).
[cited by applicant]
Richter et al., “Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer's Disease Like Tau Aggregation”, Vaccines, vol. 2, pp. 601-623 (2014).
[cited by applicant]
Ries et aL, “Convenient synthesis and application of versatile nucleic acid lipid membrane anchors in the assembly and fusion of liposomes”, Organic & Biomolecular Chemistry, vol. 13, pp. 9673-9680 (2015).
[cited by applicant]
Roberson et al., “Reducing Endogenous Tau Ameliorates Amyloid (3-Induced Deficits in an Alzheimer's Disease Mouse Model,” Science, vol. 316, pp. 750-754 (2007).
[cited by applicant]
Roder, H. et al., “Phosphorylation-Dependent Monoclonal Tau Antibodies Do Not Reliably Report Phosphorylation by Extracellular Signal-Regulated Kinase 2 at Specific Sites,” Journal of Biological Chemistry, Feb. 14, 1997…
[cited by applicant]
Roman et aL, “Therapeutic Vaccination Using Cationic Liposome-Adjuvanted HIV Type 1 Peptides Representing HLA-Supertype-Restricted Subdominant T Cell Epitopes: Safety, Immunogenicity, and Feasibility in Guinea-Bissau,” …
[cited by applicant]
Rosenmann et aL, “Tauopathy-Like Abnormalities and Neurologic Deficits in Mice Immunized with Neuronal Tau Protein,” Arch Neurol, vol. 63, pp. 1459-1467 (2006).
[cited by applicant]
Rosenmann, Hanna, “Immunotherapy for Targeting Tau Pathology in Alzheimer's Disease and Tauopathier”, Current Alzheimer Research, 10, 217-228, 2013.
[cited by applicant]
Rueda et aL, “Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes tartgeted to human DCs via Fc receptor for cancer vaccines,” Immunobiology, vol. 222, pp. 989-997 (2017).
[cited by applicant]
Sela et aL, “Therapeutic Vaccines: Realities of Today and Hopes for the Future,” Drug Discovery Today—Reviews, Therapeutic Focus, vol. 7, No. 12, pp. 664-673 (2002).
[cited by applicant]
Shane Crotty, “Follicular helper CD4 T cells (TFH)”, Annu. Rev. Immunol. 2011, 29, 621-663, www.annualreviews.org.
[cited by applicant]
Sigurdsson, Einar M., “Tau Immunotherapy”, Neurodegener Dis., 16(0), 34-38, 2016.
[cited by applicant]
Singer et al., “Immuno-PCR-Based Quantification of Multiple Phosphorylated Tau-Eprtopes Linked to Alzheimer's Disease,” Analytical and Bioanalytical Chemistry, vol. 395, No. 7, pp. 2263-2267 (2009).
[cited by applicant]
Singer, D. et al., “Characterization of Phosphorylation Dependent Antibodies to Study the Phosphorylation Dependent Antibodies to Study the Phosphorylation Status of the Tau Protein,” International Journal of Peptide Re…
[cited by applicant]
Spensieri et al., “Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses”, PNAS, vol. 110, No. 35, 14330-14335, Aug. 27, 2013.
[cited by applicant]
Tabira, “Immunization Therapy for Alzheimer Disease: A Comprehensive Review of Active Immunization Strategies,” Tohoku J. Exp. Med., vol. 220, pp. 95-106 (2010).
[cited by applicant]
Terwel et al., “Amyloid Activates GSK-3p to Aggravate Neuronal Tauopathy in Bi genic Mice,” The American Journal of Pathology, vol. 172, No. 3, pp. 786-798 (2008).
[cited by applicant]
Theunis et al., “Efficacy and Safety of a Liposome-Based vaccine against Protein Tau, Assessed in Tau. P301 L Mice That Model Tauopathy,” PLOS ONE, vol. 8, Issue 8, pp. e72301,13 pages (2013).
[cited by applicant]
Theunis et al., “Novel Phospho-Tau monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of Conformational Tauopathy Epitope”, Journal of Alzheimer's Disease, vol. 56, No. 2, pp. 585-599 (20…
[cited by applicant]
Torreilles et aL, “Binding Specificity of Monoclonal Antibody AD2: Influence of the Phosphorylation State of Tau,” Molecular Brain Research, vol. 78, pp. 181-185 (2001).
[cited by applicant]
Vanhelmont et al., “Serine-409 Phosphorylation and Oxidative Damage Define Aggregation of Human Protein Tau in Yeast,” Fems Yeast Research, vol. 10, No. 8, pp. 992-1005 (2010).
[cited by applicant]
Wassef N M et al, “Phosphate-Binding Specificities of Monoclonal Antibodies Against Phosphoinositides in Liposomes”, Molecular Immunology, (1984), vol. 21, No. 10, doi: doi:10.1016/0161-5890(84)90140-8, ISSN 0161-5890, …
[cited by applicant]
Zemlan et aL, “Monoclonal Antibody PHF-9 Recognizes Phosphorylated Serine 404 of Tau Protein and Labels Paired Helical Filaments,” Journal of Neuroscience Research, vol. 46, No. 1, pp. 90-97 (1996).
[cited by applicant]
Zheng-Fischhoefer et al., “Sequential Phosphorylation of Tau by Glycogen Synthase Kinase-3beta and Protein Kinase A at Thr212 and Ser214 Generates the Alzheimer-Specific Epitope of Antibody AT100 and Requires a Paired-H…
[cited by applicant]
Alving C R, “Antibodies to Liposomes Phospholipids and Phosphate Esters”, Chemistry and Physics of Lipids, (1986), vol. 40, No. 2-4, doi:doi:10.1016/0009-3084(86)90075-7, ISSN 0009-3084, pp. 303-314, XP025418929.
[cited by applicant]
Andronesi Ovidiu C et al, “Characterization of Alzheimer's-like paired helical filaments from the core domain of tau protein using solid-state NMR spectroscopy”, Journal of the American Chemical Society, (May 2008), vol…
[cited by applicant]
Asuni, A. et al., “Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements,” Journal of Neuroscience, Aug. 2007, pp. 9115-9129, vol. 27…
[cited by applicant]
Bentebibel et al., “Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination”, Sci Transl Med Mar. 13, 2013, 5(176), 19 pages.
[cited by applicant]
Bhaskar et aL, Tyrosine Phosphorylation of Tau Accompanies Disease Progression in Transgenic Mouse Models of Tauopathy, Neuropathology and Applied Neurobiology, vol. 36, No. 6, pp. 462-477 (2012).
[cited by applicant]
Boimel et al., “Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice,” Experimental Neuroology, vol. 224, pp. 472-485 (2010).
[cited by applicant]
Boutajangout Allal et al, “Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model”, Journal of Neuroscience, (Dec. 2010), vol. 30, No. 49, doi:doi:10.1523/JNEUROSCI.4363-10.2010,…
[cited by applicant]
Clinical Trials, “Safety Study of AADvad, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease”, https://www.clinicaltrials.gov/ct2/show/record/nct01850238?view=record, ClinicalTrials.gov Identifier: …
[cited by applicant]
Davtyan, H. et al., Alzheimer's disease Advax(CpG)—adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules, Scientific Reports ,2016, vo…
[cited by applicant]
Davtyan, Hayk, et al., “MultiTEP platform-based AD epitope vaccine activates broad repertoire of T helper cells in non-human primates”, Alzheimers Dement. 10;3, 271-283, 2014.
[cited by applicant]
De Titta et aL, “Nanoparticle Conjungation of CpG Enhances Adjuvancy from Cellular Immunity and Memory Recall at Low Dose”, PNAS, vol. 110, No. 49, pp. 19902-19907 (2013).
[cited by applicant]
Dominguez et aL, “Novel Thereapeutic Strategies Provide the Real Test for the Amyloid Hypothesis Alzheimer's Disease,” Trends in Pharmacological Sciences, vol. 23, No. 7, pp. 324-330 (2002).
[cited by applicant]
Dubois, Bruno, et al., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria”, Lancet Neurol, 13, 614-629, 2014.
[cited by applicant]
Dubois, Bruno, et al., “Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria”, Alzheimers Dement. 12(3), 292-323, 2016.
[cited by applicant]
Friedhoff et al., “Structure of tau protein and assembly into paired helical filaments”, Biochimica et Biophysica Acta 1502, pp. 122-132, 2000.
[cited by applicant]
Gandhi et aL, “A Phosphorylation-Induced Turn Defines the Alzheimer's Disease AT8 Antibody Epitope on the Tau Protein,” AngewChem Int Ed Engl, vol. 54, No. 23, pp. 6819-6823 (2015).
[cited by applicant]
Greenberg et al., “A preparation of Alzheimer paired helical filaments that displays distinct T proteins by polyacrylamide gel electrophoresis”, Proc. Natl. Acad. Sci. USA, vol. 87, pp. 5827-5831, Aug. 1990.
[cited by applicant]
Hanger et aL, “Tau phosphorylation: the therapeutic challenge for neurodegenerative disease” Trends in Molecular Medicine, vol. 15, No. 3, pp. 112-119 (2009).
[cited by applicant]
Hermanson, Greg T. Bioconjugate Techniques, 3rd Edition, Sand Diego: Elsevier Science & Technology, 2013. Chapter 6: Heterobifunctional Crosslinkers, pp. 299-339. (Year: 2013).
[cited by applicant]
Hickman et aL, “Sequence-independent Conftrol of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases,” The Journal of Biological Chemistry, vol. 286, No. 16, pp. 13966-13976 (2011).
[cited by applicant]
Hills et aL, “A Rapid-Response Humoral Vaccine Platform Exploiting pre-Existing Non-Cognate Populations of Anti-Vaccine or Anti-Viral CD4+ T Helper Cells to confirm B Cell Activation,” PLOS One, 20 pages, Nov. 18, 2016.
[cited by applicant]
Hirata-Fukae et al., “Levels of Soluble and Insoluble Tau Reflect Overall Status of Tau Phosphorylation in Vivo,” Neuroscience Letters, vol. 450, No. 1, pp. 51-55 (2009).
[cited by applicant]
Hoffman et aL, “Unique Alzheimer's Disease Paired Helical Filament Specific Epitopes Involve Double Phosphorylation at Specific Sites,” Biochemistry, vol. 36, No. 26, pp. 8114-8124 (1997).
[cited by applicant]
International Search Report and Written Opinion for App. No. PCT/US2020/029477, dated Aug. 14, 2020, 22 pages.
[cited by applicant]
International Search Report and Written Opinion for App. No. PCT/US2022/074902, dated Jan. 18, 2023, 15 pages.
[cited by applicant]
Jack, Jr., Clifford R., et al., “NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease”, Alzheimer's & Dementia, 14, 535-562, 2018.
[cited by applicant]
Jicha et al, “Camp-Dependent Protein Kinase Phosphorylations on Tau in Alzheimer's Disease,” Journal of Neuroscience, vol. 19, No. 17, pp. 7486 (1999).
[cited by applicant]
Kontsekova et al., “Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's Disease,” Alzheimer's research & therap…
[cited by applicant]
Kwong B, Liu H, Irvine DJ. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials. Aug. 2011;32(22):5134-47. (Year: 2011).
[cited by applicant]
Lee et al., “Phosphorylation of Tau by Fyn: Implications for Alzheimer's Disease,” Journal of Neuroscience, Mar. 3, 2004, vol. 24, No. 9, pp. 2304-2312.
[cited by applicant]
Lewis et aL, “Neurofibrillary Tangles, Amyotrophy and Progressive Motor Disturbance in Mice Expressing Mutant (P301L) Tau Protein,” Nature America, Inc., vol. 25, pp. 402-405 (2000).
[cited by applicant]
Lichtenberg-Kraag et al., “Phosphorylation-Dependent Epitopes of Neurofilament Antibodies on Tau Protein and Relationship with Alzheimer Tau,” PNAS, vol. 89, No. 12, pp. 5384-5388 (1992).
[cited by applicant]
Lu, Shan. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 2009, 21(3):346-351. (Year: 2009).
[cited by applicant]
Masliah et aL, “Effects of a-Synuclein Immunization in a Mouse Model of Parkinson's Disease,” Neuron, vol. 46, pp. 857-868 (2005).
[cited by applicant]
Matyas et aL, “Liposomes containing monophosphoryl lipid A: A Potent adjuvant system for inducing antibodies to heroin hapten analogs”, Vaccine, vol. 21, pp. 2804-2810 (2013).
[cited by applicant]
Muhs et al., “Liposomal Vaccines with Conformation-Specific Amyloid Peptide Antigens Define Immune Response and Efficacy in APP Transgenic Mice,” PNAS, vol. 104, No. 23, pp. 9810-9815 (2007).
[cited by applicant]
Muyllaert et aL, “Glycogen Synthase Kinase-3p, or a Link Between Amyloid and Tau Pathology?” Genes, Brain and Behavior, vol. 7, Suppl. 1, pp. 57-66 (2008).
[cited by applicant]
Muyllaert et al., “Transgenic Mouse Models for Alzheimer's Disease: the Role of GSK-3p in Combined Amyloid and Tau-Pathology,” Rev Neurol (Paris), vol. 162, No. 10, pp. 903-907 (2006).
[cited by applicant]
Nakamura et aL, “Cisphosphorylated tau as the earliest detectable pathogenic conformation in Alzheimer disease, offering novel diagnostic and therapeutic strategies,” Prion, vol. 7, No. 2, pp. 117-120 (2013).
[cited by applicant]
Neeland et al., “Incorporation of CpG into a Liposomal Vaccine Formulation Increases the Maturation of Antigen-Loaded dendritic Cells and Monocytes to Improve Local and Systemic Immunity”, Journal of Immunology, vol. 19…
[cited by applicant]
Nicolau et aL, “A Liposome-Based Therapeutic Vaccine Against (3-Amyloid Plaques on the Pancreas of Transgenic Mice,” PNAS, vol. 99, No. 4, pp. 2332-2337 (2012).
[cited by applicant]
Nicoll et aL, “Neuropathology of Human Alzheimer Disease After Immunization with Amyloid-p Peptide: A Case Report,” Nature Medicine, vol. 9, No. 4, pp. 448-452 (2003).
[cited by applicant]
Novak et aL, “Characterisation of the Antibody Response to Aadvad: The First-in-Kind Active Vaccine Against Neurofibrillary Tau Pathology”, Alzeheimer's & Dementia: The Journal of The Alzheimer's Association, vol. 12, N…
[cited by applicant]
Novak et aL, “Safety and immunogenicity of the tau vaccine AADvacl in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, phase 1 trail,” Lancet Neurol, vol. 16, pp. 123-134 (2017).
[cited by applicant]
Novak, Petr, et al., “Fundamant: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pthology in Alzheimer's disease”, Alzheimer's Research & Therapy, 10:108, 2018.
[cited by applicant]
Novak, Petr, et al., “Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead”, Front. Neurosci., 12, 798, 2018.
[cited by applicant]
Oddo et aL, “A-beta Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosporylated Tau Aggregates via the Proteasome,” Neuron, vol. 43, pp. 321-332 (2004).
[cited by applicant]
Oddo et aL, “Reduction of Soluble Abeta and Tau, but Not Soluble Abeta Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles,” Journal of Biological Chemistry, vol. 281, No. 51, pp. 39413-3942…
[cited by applicant]
Orgogozo, M.D., J.M., et al., “Subacute meningoencephalitis in a subset of patients with AD after AB42 immunization”, Neurology 61, 46-54, 2003.
[cited by applicant]
Otvos, L. et al., “Monoclonal Antibody PHF4 Recognizes Tau Protein Phosphorylated at Serine Residues 396 and 404,” Journal of Neuroscience Research, Jan. 1, 1994, vol. 39, pp. 669-673.
[cited by applicant]
Zaman, Mehfuz et al. “Novel platform technology for modular mucosal vaccine that protects against
[cited by applicant]
Alving, Carl R., et al, “Lipid A and liposomes containing lipid A as antigens and adjuvants,” Journal of Vaccine, vol. 26 (2008) pp. 3036-3045.
[cited by applicant]
Archuleta, Amy et al., “Optimized Protocol to Make Phospho-Specific Antibodies that Work,” Methods in Molecular Biology, vol. 717 (Jan. 2011) p. 69-88. Abstract Only.
[cited by applicant]
Berg, Leonard, “Clinical Dementia Rating (CDR),” Psychopharmacol Bull. 1988;24(4):637-639.
[cited by applicant]
Brumbaugh, Kathy et al., “Overview of the Generation, Validation, and Application of Phosphosite-Specific Antibodies,” Signal Transduction Immunohistochemistry: Methods and Protocols, Methods in Molecular Biology, vol. …
[cited by applicant]
Dick, Fritz “Acid CleavagefDeprotection in Fmoc/tBu Solid-Phase Peptide Synthesis,” Methods in Molecular Biology, vol. 35 (1994) pp. 63-72.
[cited by applicant]
Hermanson, Greg T. “Chapter 6: Heterobifunctional Crosslinkers,” Bioconjugate Techniques, 3rd Edition, Elsevier Science & Technology (2013) pp. 299-339.
[cited by applicant]
Iqbal, Khalid et al. “Tau Pathology in Alzheimer Disease and other Tauopathies,” Biochimica et Biophysica Acta, vol. 1739 (2005) pp. 198-210.
[cited by applicant]
Jovanovic, Jasmina N., “Chapter 4 Phosphorylation Site-Specific Antibodies as Research Tools in Studies of Native GABA Receptors,”, NCBI Bookshelf . A service of the National Library of Medicine, National Institutes of …
[cited by applicant]
Kwong, Brandone et al., “Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy,” Biomaterials, vol. 32, issue 22 (Aug. 2011) pp. 5134-5147.
[cited by applicant]
Novak, Petr et al., “ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease,” Nature Aging, vol. 1 (Jun. 2021) pp. 521-534.
[cited by applicant]
Smet, Caroline “These,” In Docteur DE L'Universite De, Absract Only (Oct. 18, 2004) 3 pages.
[cited by applicant]
Smet, Caroline et al. “The Peptidyl Prolyl cis/trans-Isomerase Pinl Recognizes the Phospho-Thr212-Pro213 Site on Tau,” Biochemistry, vol. 43 (2004) pp. 2032-2040.
[cited by applicant]
Study: ACI-35-LEGOO5-002 “Specificity of the ACI-35 immunogenicity in TPLH mice tested on different phospho- and non-phospho-Tau peptides,” AC Immune, 2011, pp. 1-8.
[cited by applicant]
Vassilakopoulou, Vyronia et al. “Peptide-Based Vaccines For Neurodegenerative Diseases: Recent Endeavors And Future Perspectives,” Journal of Vaccines, vol. 9, (2021) pp. 1-27.
[cited by applicant]
Tesi, “Why Do So Many Alzheimer's Clinical Trials Fail?” Clinical Leader, https://www.clinicalleader.com/doc/why-do-so-many-alzheimer-s-clinical-trials-fail-0001, (2003) 3 pages.
[cited by applicant]
Silva et al., “Alzheimer's disease: risk factors and potentially protective measures,” J Biomed Sci. (2019) 26:33 (11 pages).
[cited by applicant]